Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!
Gå frakoblet med Player FM -appen!
Theralase Explores Synergistic Drug Combinations for Cancer Treatment
MP3•Episoder hjem
Manage episode 436671949 series 2891889
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to announce a significant advancement in cancer treatment. The company's lead drug formulation, Rutherrin, has demonstrated a remarkable ability to enhance the efficacy of Cisplatin, a commonly prescribed chemotherapy drug, in treating chemotherapy-resistant Non-Small Cell Lung Cancer in a preclinical animal model. DuMoulin-White detailed the experimentation process, where mice were divided into two groups: a control group treated with Cisplatin alone and an active group treated with a combination of Cisplatin and Rutherrin. The results were striking. The mice in the active group showed a significantly higher enhancement of Cisplatin efficacy, marked by a notable increase in overall survival compared to the control group. The statistical significance of these results highlights the potential impact of Rutherrin in improving treatment outcomes for patients with aggressive NSCLC. Theralase Technologies believes that the efficacy of Rutherrin could be further improved by combining it with additional treatments such as radiation or Metformin, which could activate Rutherrin® while it resides in NSCLC cells. This promising preclinical data lays the groundwork for future studies and potential clinical applications, offering new hope for patients battling resistant forms of lung cancer. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episoder
MP3•Episoder hjem
Manage episode 436671949 series 2891889
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to announce a significant advancement in cancer treatment. The company's lead drug formulation, Rutherrin, has demonstrated a remarkable ability to enhance the efficacy of Cisplatin, a commonly prescribed chemotherapy drug, in treating chemotherapy-resistant Non-Small Cell Lung Cancer in a preclinical animal model. DuMoulin-White detailed the experimentation process, where mice were divided into two groups: a control group treated with Cisplatin alone and an active group treated with a combination of Cisplatin and Rutherrin. The results were striking. The mice in the active group showed a significantly higher enhancement of Cisplatin efficacy, marked by a notable increase in overall survival compared to the control group. The statistical significance of these results highlights the potential impact of Rutherrin in improving treatment outcomes for patients with aggressive NSCLC. Theralase Technologies believes that the efficacy of Rutherrin could be further improved by combining it with additional treatments such as radiation or Metformin, which could activate Rutherrin® while it resides in NSCLC cells. This promising preclinical data lays the groundwork for future studies and potential clinical applications, offering new hope for patients battling resistant forms of lung cancer. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episoder
Wszystkie odcinki
×Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.